BioPharmaTrend
Latest News
All Topics
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures
  • Industry Movers
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Newsletter
Login/Join
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures
  • Industry Movers

The Promise Of Cell Technologies In Immunotherapy

by Irina Bilous   •   Feb. 9, 2020  

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

   Biopharma insight   
Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email   |  

The number of immunotherapies in clinical trial rolls over 5000 now, and immunology has become a common approach in some cancers. Cell technologies, as a growing sub-field in the immunotherapy landscape, have progressed considerably and now represent a $26 billion financial opportunity by 2030, according to a report by Roots Analysis.

#advertisement
AI in Drug Discovery Report 2025

Evolutionarily, the immune system has adapted to distinguish between foreign or tumor antigens and the body's own cells. To prevent autoimmune reaction, T-lymphocytes carry on special PD-1 (programmed cell death-1) receptor, that verify foes before attacking them. Insidious cancer cells often express a ligand to this receptor - PD-L1, triggering intracellular mechanisms that block T-cells response. Inhibitors for this PD-1/PD-L1 and other checkpoint pathways (Opdivo, Keytruda, Yervoy) are being routinely used.

Thanks to the success of checkpoint therapies, immunotherapy ramped up its popularity, shifting toward the development of cell therapies. The Car T-cells have shown success in treating blood cancers in patients who have not responded to almost any of available treatments. Car T-cells are engineered to express Chimeric Antigen Receptors with a high affinity to tumors antigens. Despite groundbreaking results, the technology has its own limitations and required significant improvements. 

Common Car T-cells have an autologous origin, implying that cells must be retrieved from the patient's blood, modified and infused back to the bloodstream, that takes about three weeks and enormous costs. Making allogeneic, also called of-the-shelf, therapies is a new challenge for biotech companies. Century Therapeutics raised $215 million from Bayer for this purpose in July 2019, focusing on producing Car T-cells  from induced pluripotent stem cells (iPSC). On the other hand, Cellectis and Allogene Therapeutics employ gene editing technologies to modify T-cells derived from healthy donors. This will enable companies to transform complex and costly personalized treatments into more unified treatment schemes, and ‘off-the-shelf’ cell therapies.

Both approved therapies (Novartis’ Kymriah and Gilead’s Yescarta) are targeting CD19 antigens on the surface of B lymphocytes. However, several patients have died during clinical trials of such drugs due to the cytokine release syndrome and brain bleeding. New generation of CAR T-cells should make the cure more controllable. As an example, Bellicum Pharmaceuticals employs a safety switch ensuring T cells are activated only in the presence of the additional drug, rimiducid.

Furthermore, Car T-cells are weak when coping with solid tumors, and cancers might become resistant and relapse. To overcome the barriers,  Autolux created a cell line that simultaneously targets CD19 and CD22 antigens. Cellyad combines properties of NK cells and T-lymphocytes, constructing NKR T-cells that are able to recognize eight receptors expressed in tumors and surrounding tissues. BioNTech boost Car T-cells with RNA encoded claudin 6, a protein which expressed specifically on the surface of certain cancers, forcing them to penetrate solid tumors.

Companies strive to make T-cell therapy safer and expand it for more cancers and even apply against autoimmune diseases.  Advances in gene technologies, such as CRISPR, and the emergence of IP stem cells work well for immuno-oncology, allowing us to create precise cell therapies. 

Below we have summarized several biotech companies focusing on discovery and development of cell therapies. If you want to add your company to this list, or update information in the existing company profile, please, use our Editor Tool. 

Autolus Bluebird Bio BrainStorm Cell Therapeutics Century Therapeutics
Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

You may also be interested to read:

The Key Role Of Stem Cells In Lethal Gastric Cancer Revealed
by Caroline Green

 

#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Newsletter
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.